COMMUNIQUÉS West-GlobeNewswire

TerrAscend Reports Fourth Quarter and Full Year 2024 Financial Results
06/03/2025
Fourth Quarter Net Revenue of $74.4 million, up 0.3% from $74.2 million in the third quarter of 2024 Fourth Quarter Gross Profit Margin of 50.2%, up 140 basis points from 48.8% in the third quarter of 2024 Full Year [...]
Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results
06/03/2025
– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 – – VCN-01 development bolstered by FDA award of Fast Track [...]
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
06/03/2025
ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides multiple [...]
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
06/03/2025
First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target [...]
Jushi Holdings Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
06/03/2025
Full Year 2024 Net Loss of $48.8 Million Compared to Net Loss of $65.1 Million in 2023 Full Year 2024 Adjusted EBITDA of $46.2 Million Compared to $40.8 Million in 2023 Increased Quarterly and Annual Operational Cash [...]
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
06/03/2025
Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025 Cash of approximately $68.6 million expected to fund [...]
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
06/03/2025
GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out
06/03/2025
– Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization – SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company [...]
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
06/03/2025
Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus ( HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET [...]
Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results
06/03/2025
TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
06/03/2025
No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study without any modifications. SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. ( [...]
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
06/03/2025
Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Expansion of investigator sponsored “window of opportunity” trial into newly diagnosed glioblastoma patients [...]
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
06/03/2025
– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 [...]
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
06/03/2025
FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX [...]
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
06/03/2025
Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
06/03/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 6 mars 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général [...]
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD
06/03/2025
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD NANTES, France – March 6, 2025, 6:00pm CET - OSE Immunotherapeutics recently hosted a webinar featuring key opinion leaders (KOLs [...]
Webinaire post-ECCO d’OSE Immunotherapeutics Lusvertikimab dans le paysage thérapeutique des MICI : Le point de vue des leaders d’opinion
06/03/2025
Webinaire post-ECCO d’OSE Immunotherapeutics Lusvertikimab dans le paysage thérapeutique des MICI : Le point de vue des leaders d’opinion NANTES, France, 6 mars 2025, 18 heures – OSE Immunotherapeutics a récemment [...]
Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
06/03/2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]

Pages